Announcement • 1h

Roche Receives FDA Clearance For Elecsys Ptau217 Blood Test For Alzheimer’s Disease Assessment

Roche announced that the U.S. Food and Drug Administration (FDA) has cleared the Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test, providing clinicians across primary and specialty care with a single blood-based option to aid in identifying amyloid pathology associated with Alzheimer's disease in individuals 55 years and older with signs, symptoms, or complaints of cognitive decline. Developed in collaboration with Eli Lilly and Company, Elecsys pTau217 is the first and only FDA-cleared, single-biomarker blood test that supports both rule-in and rule-out assessment of amyloid pathology using the same validated clinical cutoffs across primary and specialty care settings. The assay provides positive, intermediate and negative result categories to support assessment of the likelihood of amyloid pathology. Results are interpreted in conjunction with clinical information and other relevant findings as part of the Alzheimer's disease diagnostic pathway. Healthcare providers across primary and specialty care now have access to the first and only FDA-cleared, single-biomarker blood test designed to support both rule-in and rule-out assessment of amyloid pathology. The test is designed for use across Roche's more than 4,500 cobas laboratory instruments in the United States, enabling broad access through existing laboratory infrastructure. The Elecsys pTau217 blood test helps address these barriers by providing a minimally invasive blood-based option that can be incorporated into existing clinical and laboratory workflows. The test may help clinicians assess the likelihood of amyloid pathology earlier in the disease and diagnostic pathway and identify patients who should be considered for additional evaluation or specialist referral. Following FDA clearance, Elecsys pTau217 may help healthcare providers and health systems support clinical decision-making across primary and specialty care settings through a single-biomarker blood test that provides positive, intermediate or negative amyloid pathology results to aid clinical assessment of amyloid pathology. Help identify appropriate next steps by distinguishing patients with a high or low likelihood of amyloid pathology and those who should be considered for further testing. Support a more efficient diagnostic pathway by providing a minimally invasive blood-based option that may help clinicians determine when additional evaluation, including PET imaging or CSF testing, is appropriate. Evaluated in individuals 55 years and older with signs, symptoms or complaints of cognitive decline associated with Alzheimer's disease, Elecsys pTau217 demonstrated high agreement with amyloid PET imaging, providing clinicians with a minimally invasive option for assessing amyloid pathology. As a single-assay solution, Elecsys pTau217 simplifies laboratory implementation by using one biomarker and one set of validated clinical cutoffs to support both rule-in and rule-out assessment of amyloid pathology. Roche refers to this approach as the "Power of One"—one assay, one biomarker and one set of validated clinical cutoffs designed to simplify Alzheimer's assessment while expanding access to blood-based testing. Elecsys pTau217 is not intended to be used as a stand-alone test. Results should be interpreted in conjunction with other diagnostic tools and clinical information. The safety and effectiveness of the assay have not been established for predicting development of dementia or other neurologic conditions or for monitoring the effect of therapeutic products. With more than 4,500 Roche cobas instruments already installed in U.S. clinical laboratories, Elecsys pTau217 is designed to integrate into existing laboratory workflows without requiring additional instrumentation, supporting rapid implementation and broad access following FDA clearance. Roche's Alzheimer's portfolio includes Elecsys pTau217, Elecsys pTau181, Elecsys pTau181/Abeta42 ratio, Elecsys tTau/Abeta42 ratio, a portfolio of neurology research-use-only (RUO) assays supporting ongoing biomarker research, Trontinemab, an investigational Brainshuttle amyloid beta-targeting monoclonal antibody designed for enhanced brain delivery and currently being evaluated in two phase III studies in early Alzheimer's disease, and Nivegacetor, an investigational, oral gamma-secretase modulator designed to reduce amyloid accumulation and currently in phase II development. Together, these diagnostics and investigational medicines reflect Roche's strategy to advance earlier diagnosis and treatment of Alzheimer's disease.

Roche Holding AG Stock Price

ROP Share Price Performance

ROP Community Narratives

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Trending Discussion

Recently Updated Narratives

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

ROP: Partnership And Pipeline Execution Risk Will Likely Cap Future Upside

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

Snowflake Analysis

Roche Holding AG Key Details

About ROP

Recent ROP News & Updates

Roche Receives FDA Clearance For Elecsys Ptau217 Blood Test For Alzheimer’s Disease Assessment

Genentech to Expand Hillsboro Facility With $750 Million Investment for Advanced Injectables

Genentech Reaches Construction Milestone for $2 Billion North Carolina Biomanufacturing Facility

Recent updates

Roche Holding AG Competitors

Novartis

Lonza Group

Galderma Group